Kobe University Biosignal Research Center has discovered the first molecular evidence that cell motility, a key component in immunity, development, and other fundamental biological mechanisms, is regulated by a physical factor-membrane tension stress.
This finding is expected to have significant implications for treating infections and malignant tumours, and have been published on-line in Nature Cell Biology.
Led by Prof Toshiki Itoh, Assistant Prof Kazuya Tsujita and other researchers in Prof Itoh’s laboratory conducted studies using a cultured tumour cell line, and showed that tension stress on the plasma membrane plays a major role in the regulation of cell motility.
More specifically, this group showed that formin-binding protein-17 (FBP17), a protein known to bend the plasma membrane, acts as a tension sensor that mediates the direction of cell migration.
In the human body, cell motility is regulated to support immune homeostasis and growth.
For example, when bacteria or viruses enter the body, macrophages, neutrophils, and other immune cells identify, trace, and eliminate them.
During development, when a fertilised egg undergoes proliferation and differentiation, new cells migrate to the appropriate sites via strictly controlled mechanisms.
Disruption of the mechanisms regulating cell motility may be a key factor in cancer cell metastasis.
Thus, elucidation of the mechanisms governing cell movement will be a critical step toward overcoming malignant tumours.
Prof Itoh says, “We are promoting research from a less studied perspective to identify new approaches to cancer treatment.”
Source: Kobe University
We are an independent charity and are not backed by a large company or society. We raise every penny ourselves to improve the standards of cancer care through education. You can help us continue our work to address inequalities in cancer care by making a donation.
Any donation, however small, contributes directly towards the costs of creating and sharing free oncology education.
Together we can get better outcomes for patients by tackling global inequalities in access to the results of cancer research.
Thank you for your support.